AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00003440 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00003440 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03662165 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: A text was sent three times, one week apart, first in Kiswahili, then in English and then again in Kiswahili, and read: You can now self-test at home or in the clinic for HIV using a new test kit available from all North Star Alliance clinics in Kenya. Your health, our priority. Participants who came to any North Star clinic in Kenya in the intervention arm were given a demonstration of the self-testing kit and then offered a choice among (1) the standard provider-administered blood-based HIV test; (2) the self-administered oral HIV test for use in the clinic with provider supervision; or (3) the self-administered oral HIV test kit for home use with phone-based post-test counseling.
Study NCT03662165 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Standard of Care
Description: Those randomized to the enhanced Standard of Care (SOC) arm received the SOC message reminding clients about HIV testing sent three times, one week apart first in Kiswahili, then in English and then again in Kiswahili. The message read: North Star Alliance East Africa would wish to kindly remind you to visit any of our roadside wellness centres for HIV testing. Your health, our priority. Participants who came to any North Star clinic in the enhanced SOC arm only offered the standard provider-administered blood-based HIV test.
Study NCT03662165 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Standard of Care
Description: Those randomized to the traditional Standard of Care (SOC) arm received the SOC message reminding clients about HIV testing sent one time in both Kiswahili, then in English and Kiswahili simultaneously. The message read: North Star Alliance East Africa would wish to kindly remind you to visit any of our roadside wellness centres for HIV testing. Your health, our priority. Participants who came to any North Star clinic in the traditional SOC arm only offered the standard provider-administered blood-based HIV test.
Study NCT02181816 — intervention group
Intervention type: DRUG
Intervention: Azilsartan/Amlodipine
Description: Azilsartan/Amlodipine combination tablets LD \& HD
Study NCT01194713 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep deprivation
Description: subjects will undergo one night of full sleep deprivation
Study NCT00169689 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: rTMS, repetitive transcranial magnetic stimulation
Description: 10 Hz rTMS (10.000 stimuli) over left dorsolateral prefrontal cortex
Study NCT00169689 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: rTMS
Description: repetitive transcranial magnetic stimulation, 10 Hz, 10.000 stimuli, 2 weeks
Study NCT04187300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Increasing doses of semaglutide administered s.c. (subcutaneouly, under the skin) once weekly for 20 weeks
Study NCT01612468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: 1.8 mg/day subcutaneous
Study NCT01612468 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1.8 mg/day subcutaneous
Study NCT03182647 — intervention group
Intervention type: PROCEDURE
Intervention: Surgically treatment of the ACL
Description: Surgical initial ACL treatment
Study NCT03182647 — intervention group
Intervention type: OTHER
Intervention: Non surgical initial ACL treatment
Description: Non surgical initial ACL treatment
Study NCT03268434 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: D-MCT
Description: Metacognitive Training for Depression (D-MCT), 8 sessions (60min); once a week over a period of 8 weeks. Metacognitive Training for depression (D-MCT) is a low-threshold, easy to administer group intervention. It aims at the reduction of depressive symptoms by changing cognitive biases; not only biases targeted in cognitive behavioral therapy but also those identified by basic research.
Study NCT03268434 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive remediation
Description: A computerized cognitive remediation program that covers several cognitive domains, such as attention, visuomotor skills, and Memory. The difficulty level adapts automatically to the performance level of each patient. At the end of each session, the patient receives individual feedback on his or her performance; 8 sessions (60min), once a week over a period of 8 weeks
Study NCT02219282 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal Mask Unique insertion
Description: Before insertion the laryngeal mask used in daily routine (Laryngeal Mask Unique) was lubricated with a water-based gel and the cuff was completely deflated. After induction when BIS values were between 40 and 60 and sufficient chin relaxation was obtained for patients weighing less than 50 kg no. 3 LMU, for those between 50-90 kg no. 4 and for patients above 90 kg no. 5 LMU was inserted by an anesthetist with more than three years experience.
Study NCT02219282 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Unique insertion
Description: Before insertion the laryngeal mask used in daily routine (Laryngeal Mask Unique) was lubricated with a water-based gel and the cuff was completely deflated. After induction when BIS values were between 40 and 60 and sufficient chin relaxation was obtained for patients weighing less than 50 kg no. 3 LMU, for those between 50-90 kg no. 4 and for patients above 90 kg no. 5 LMU was inserted by an anesthetist with more than three years experience.
Study NCT03877562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Olanzapine 10 mg oral tablet
Study NCT03877562 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olanzapine
Description: Olanzapine 10 mg oral tablet
Study NCT03877562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT118335
Description: CORT118335 600 mg oral tablets administered as 2 X 300 mg or 6 X 100 mg tablets
Study NCT03877562 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching CORT118335, 2 or 6 oral tablets, depending on the CORT118335 tablet strength available
Study NCT00922480 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fimasartan
Description: Fimasartan 60 \~ 120mg/po take one tablets once a day
Study NCT00922480 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan (Control)
Description: Losartan 50 mg \~ 100 mg/po, take one tablets once a day
Study NCT02819635 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Film-coated tablet for oral administration
Study NCT02819635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Film-coated tablet for oral administration
Study NCT02819635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Film-coated tablet for oral administration
Study NCT01687179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus and Hydroxychloroquine 200 mg
Description: This will be a phase I dose escalation study of the combination of Sirolimus (2 mg adjusted to keep trough levels between 5-15 ng/ml) and Hydroxychloroquine 200 mg taken orally daily.
Study NCT01687179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus and Hydroxychloroquine 400 mg
Description: Once safety is established with the lower dose, (Sirolimus and Hydroxychloroquine 200 mg), subjects will receive Sirolimus 2 mg (adjusted to keep trough levels between 5 to 15 ng/ml) and hydroxychloroquine 200 mg twice a day.
Study NCT01429818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride/metformin
Description: 4/1000 mg tablets once a day foe eight weeks
Study NCT01429818 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 1000 mg tablets once daily for eight weeks
Study NCT02603367 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communication Intervention
Description: Undergo communication coaching
Study NCT02603367 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive COMFORT communication curriculum
Study NCT02603367 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychosocial Support for Caregiver
Description: Undergo communication coaching
Study NCT02603367 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study NCT03687645 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Hyperpolarised MRI
Description: Hyperpolarized (HP) 13C MR is an advanced imaging technique that allows monitoring of dynamic metabolic processes non-invasively. Hyperpolarisation is a process that provides dramatic gains in sensitivity (>10,000) of MRI signal collected from 13C-labelled substrates that can be injected into living systems, allowing in-vivo metabolism for the first time to be observed in real-time using imaging.
Study NCT02302352 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: Probiotic 1g once a day by mouth for 8 weeks
Study NCT02302352 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin 1g, manufactured to mimic the probiotic, once a day by mounth for 8 weeks
Study NCT01887067 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal denervation therapy
Study NCT02428855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Study NCT00244270 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: totally implantable vascular access device
Description: totally implantable vascular access device
Study NCT01274819 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic Light
Description: Dynamic Light Application (DLA) is a light application which exposes the subject in the room to a varying light intensity and light temperature during the day thus mimicking a natural daylight exposure.
Study NCT03442036 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Suture-Method Technique
Description: Perineural catheters are attached to the back of a hollow suture-shaped needle that pulls the catheter adjacent to the target nerve
Study NCT03442036 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Through-the-Needle Technique
Description: Perineural catheters are inserted through a straight hollow-bore needle
Study NCT01442194 — intervention group
Intervention type: DRUG
Intervention: other disease-modifying therapy
Study NCT01442194 — intervention group
Intervention type: DRUG
Intervention: Fingolimod
Study NCT04428463 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tachosil
Description: tympanic membrane perforation repair using Tachosil patch under local anesthesia
Study NCT04428463 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fascia and cartilage
Description: tympanic membrane perforation repair using fascia and cartilage under general anesthesia
Study NCT01788384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin Phosphate / Benzoyl Peroxide Gel
Description: Dosage form: topical gel Dosage: One pea-sized amount will be applied onto six areas of the face (chin, left cheek, right cheek, nose, left forehead, right forehead), avoiding the eyes, lips and mucous membranes.
Study NCT01788384 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%
Description: Dosage form: topical gel Dosage: One pea-sized amount will be applied onto six areas of the face (chin, left cheek, right cheek, nose, left forehead, right forehead), avoiding the eyes, lips and mucous membranes.
Study NCT01788384 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Vehicle Gel)
Description: Dosage form: topical gel Dosage: One pea-sized amount will be applied onto six areas of the face (chin, left cheek, right cheek, nose, left forehead, right forehead), avoiding the eyes, lips and mucous membranes.
Study NCT03651453 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision aid
Description: Participants in the experimental arm will receive the PrEP decision aid.
Study NCT03651453 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard harm reduction information
Study NCT02200354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed with bevacizumab
Study NCT02999867 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: triticale and mung bean
Description: subjects are assigned to intake of triticale and mung bean for 30 days
Study NCT02999867 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: adzuki bean
Description: subjects are assigned to intake of adzuki bean for 30 days
Study NCT03283124 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pelvic floor reconstructive surgery
Description: transvaginal mesh implantation for pelvic organ prolapse
Study NCT02614365 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Cardiovascular fitness
Study NCT02614365 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretch exercise
Description: Muscle stretch
Study NCT00823823 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bivalved cast
Description: Circumferential cast will be applied following closed reduction and then bivalved using a cast saw
Study NCT00823823 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Circumferential cast
Description: Circumferential cast will be applied following closed reduction
Study NCT00066768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: suramin
Description: Given IV
Study NCT00066768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV
Study NCT00066768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT00066768 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00066768 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT03044938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salbutamol
Description: Salbutamol or albuterol is a short-acting β2 adrenergic receptor agonist used for the relief of bronchospasm in conditions such as asthma and chronic obstructive pulmonary disease.
Study NCT03044938 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Neutral preparation for pharmacological effects, given in substitution of a medicine, for the purpose of provoking or controlling reactions, ger. Of a psychological nature, accompanying such a therapeutic procedure.
Study NCT04107415 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: yoga
Description: A total of 12 yoga sessions, 2 sessions a week for 6 weeks, was applied to the patients in the experimental group.
Study NCT00319280 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bonesubstitution (Calcibon, Iliac Crest Bonegraft, control)
Description: Osteotomysite are filled with Calcibon (an injectable calcium phosphate cement) or Minced Iliac Crest Bonegraft og local graft as control
Study NCT00319280 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bonesubstitution (Calcibon, Iliac Crest Bonegraft, control)
Description: Osteotomysite are filled with Calcibon (an injectable calcium phosphate cement) or Minced Iliac Crest Bonegraft og local graft as control
Study NCT03016208 — intervention group
Intervention type: DRUG
Intervention: Misoprostol vaginal insert
Study NCT00050648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daclizumab
Description: 1mg/kg medication every other week on the odd week (week 1-13).
Study NCT00050648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Description: 2mg/kg/day orally from Day 0 until Day 90 or a total of 13 weeks.
Study NCT00050648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine and Daclizumab
Description: 1mg/kg plus low dose cyclosporine (2 mg/kg/day)
Study NCT01039077 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic gastric banding
Description: Laparoscopic gastric banding for the treatment of morbid obesity.
Study NCT01186796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Secretagogue combinations are assigned in randomized double-blind order within-subject to include the following four conditions:~(i)L-arginine (30 gm i.v. over 30 min from 0930 h to 1000 h) followed by 5 mL bolus of NS at 1000 h; (ii) L-arginine (30 gm i.v. over 30 min from 0930 h to 1000 h) followed by GHRH and Ghrelin (both at dose of 0.3 mcg/kg bolus i.v.) at 1000 h; (iii) L-arginine (30 gm i.v. over 30 min from 0930 h to 1000 h) followed by GHRH (0.3 μg/kg bolus i.v.) at 1000 h; (iv) L-arginine infusion (30 gm i.v. over 30 min from 0930 h to 1000 h) followed by Ghrelin (0.3 μg/kg bolus i.v.) at 1000 h.~\*\*Ghrelin dosage is based on 70 kg subject.Total exposure of Ghrelin will be 42 mcg total dose for 2 subject visits (21 mcg per visit).
Study NCT04602169 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVI
Description: PV re-isolation will be conducted according to the CLOSE-protocol. Point-by-point radiofrequency (RF) delivery will be performed aiming for a contiguous circle enclosing all PVs. RF will be delivered in a power-controlled mode (without ramping) using 35-40 Watt. The irrigation rate will be set at 30 ml/min. RF will be delivered until an ablation index (AI) of ≥400 is reached at the posterior wall and ≥550 at the anterior wall. In case of dislocation, a new RF application reaching the AI target will be applied. Maximal intertag distance between two neighboring lesions is 6 mm. In case of intra-esophageal temperature (T°) rise >38.5°C during posterior LA wall ablation, RF delivery will stopped at an AI of 300. In the absence of first pass isolation, touch-up ablation was applied until PVI. In case of reconnection during the waiting time or during the adenosine test, the site of reconnection will be located and treated with touch-up ablation until adenosine proof PVI is reached.
Study NCT04602169 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVI + SVC
Description: Patients in this group receive PVI according to the CLOSE protocol. In addition, they will receive an SVC isolation. The circular mapping catheter will be introduced in the superior vena cava to determine baseline electrical activity and to confirm definite entrance and exit block after ablation. Ablation will be performed proximally to the SVC/right atrial junction with the contact force-catheter using circular point-by-point radiofrequency delivery with a power setting of 35W, targeting an AI ≥400. High output (25 mA) pacing will be applied before each RF application to check for phrenic nerve stimulation. In areas of phrenic nerve capture ablation will be avoided even in case of incomplete isolation.
Study NCT03969849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN5713-5714-5715
Description: Part A: Cohort 1 - 3: Single sequential ascending subcutaneous (SC) dose Part A: Cohort 4: Single intravenous (IV) dose Part B: Single SC dose
Study NCT03969849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: Part A: Cohort 1 - 3: Single sequential ascending subcutaneous (SC) dose Part A: Cohort 4: Single intravenous (IV) dose Part B: Single SC dose
Study NCT02171962 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zilver® PTX® Drug-Eluting Peripheral Stent
Description: Zilver® PTX® Drug-Eluting Peripheral Stent for treatment of lesions of the above-the-knee femoropopliteal artery
Study NCT02806089 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Handheld dynamometer
Description: Evaluation of muscle strength
Study NCT02806089 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Creatinine index
Description: Evaluation of muscle mass using plasma creatinine level
Study NCT03290066 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: kinesiotape
Description: For the Kinesio taping group, a piece of Kinesio tape 5 cm in width and 7-8 cm in length will be applied right from below the navel and will reach to where the pubic hair begins, and another piece of tape 10 cm in length will be applied to make a cross shape with the first piece. A tape of 20cm in length will be placed horizontally to the lower back.
Study NCT03290066 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Participants will note the usual self-care used to relief pain (NSAIDs, heat, massage therapy.....).
Study NCT02806089 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical bioimpedance analysis
Description: Evaluation of lean body mass
Study NCT02806089 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Voorrips score questionnaire
Description: Evaluation of physical activity
Study NCT02806089 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inflammatory and nutritional status
Description: Evaluation of C reactive protein and albumin
Study NCT04429165 — intervention group
Intervention type: OTHER
Intervention: collection of Patient Reported Outcome (PRO) data
Description: collection of Patient Reported Outcome (PRO) data by questionnaires